Aegerion Pharmaceuticals, Inc. (AEGR: Quote) said Friday that it has priced an underwritten public offering of about 2.7 million shares of common stock at a price to the public of $26.64 per share.
The net proceeds to Aegerion from the offering are expected to be about $67.9 million, after deducting underwriting discounts and commissions.
The offering is expected to close on January 16.
Aegerion has granted the underwriters a 30-day option to purchase up to an aggregate of 405,710 additional shares of common stock.
The company expects to use the net proceeds from the offering to fund activities directed at commercial launch of JUXTAPID Capsules in the United States; pursuing approval of its Marketing Authorization Application submission with the European Medicines Agency for lomitapide, and, if it is approved, commercial activities in the European Union; expansion of operations in certain countries to pursue regulatory approval of lomitapide and to conduct sales on a named-patient-sales basis, where permitted; advancement of the clinical development of lomitapide; and business development activities; with any remainder to fund working capital, capital expenditures and for general corporate purposes.
To receive FREE breaking news email alerts for Aegerion Pharmaceuticals Inc. and others in your portfolio
by RTT Staff Writer
For comments and feedback: editorial@rttnews.comBusiness News